Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinedge LLC

Neither a doctor nor a teaching hospital

Research payments

$7,518,995

1,182 payments

Through program year 2025, Clinedge LLC is reported as receiving $7,518,995 in research payments, across 1,182 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$187,413	53
2024	Research	$776,113	126
2023	Research	$2,110,810	274
2022	Research	$2,748,812	527
2021	Research	$1,695,847	202

Breakdown

Who paid Research payments · program years 2021–2025

Eli Lilly and Company $2,930,860 41 payments
GlaxoSmithKline, LLC. $1,269,357 306 payments
ITI, Inc. $674,257 74 payments
Genentech, Inc. $316,020 39 payments
Sage Therapeutics, Inc. $290,265 37 payments
Sumitomo Pharma America, Inc. $268,761 106 payments
Teva Pharmaceuticals USA, Inc. $249,938 214 payments
Hoffmann-La Roche Limited $208,601 52 payments
Myovant Sciences GmbH $166,865 47 payments
Pfizer Inc. $163,037 24 payments

Studies the money was for Research payments · program years 2021–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $908,322 3 payments
A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $521,487 116 payments
PH Iib of Astegolimab in COPD $519,560 89 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $470,993 4 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $402,743 1 payment
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the $374,320 100 payments
Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $323,787 1 payment
An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $317,362 35 payments
Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $306,691 1 payment
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $273,557 31 payments

What the money was spent on Research payments · program years 2021–2025

Patient care $1,754 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.